Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment Academic Article Article uri icon

Overview

MeSH Major

  • Alzheimer Disease
  • Amyloid
  • Brain
  • Cognition Disorders
  • Positron-Emission Tomography

abstract

  • Objectives: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Methods: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau231), amyloid beta (Aβ) Aβ42/Aβ40 ratio, isoprostane (IP) as well as P-tau231/Aβ42/40 and T-tau/Aβ42/40 ratios. Results: At baseline and at follow-up MCI-AD showed higher levels P-tau231, T-tau, IP, P-tau231/Aβ42/40 and T-tau/Aβ42/40 ratios and lower Aβ42/Aβ40 than MCI-MCI or NL-NL. Baseline P-tau231 best predicted MCI-AD (80%, p < 0.001) followed in accuracy by P-tau231/Aβ42/40 and T-tau/Aβ42/40 ratios (both 75%, p's < 0.001), T-tau (74%, p < 0.001), Aβ42/Aβ40 (69%, p < 0.01), and IP (68%, p < 0.01). Only IP showed longitudinal effects (p < 0.05). Conclusions: P-tau231 is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials. © 2007 Elsevier Inc. All rights reserved.

publication date

  • May 2009

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/j.neurobiolaging.2007.08.010

PubMed ID

  • 17889968

Additional Document Info

start page

  • 682

end page

  • 690

volume

  • 30

number

  • 5